Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES 简体中文 中文 हिन्दी HI
Sign Up
Log in
Halozyme Therapeutics Inc banner

Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 130.915 USD -0.2% Market Closed
Market Cap: $15.5B
Write Note Create Alert

Intrinsic Value

Is HALO undervalued or overvalued?

See the intrinsic value estimate for Halozyme Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

HALO Intrinsic Value
LOCKED
Unlock
Today vs. history

HALO looks overvalued.
But is it expensive by its own standards?

See how today’s valuation compares with HALO’s past valuations and how the stock performed after similar periods.

See what happened next Free account required
Monitor HALO
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value
Get notified when the price drops into your buy zone
Current Price $130.92
Intrinsic Value Locked
Margin of Safety 20% Locked
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to HALO

Fundamental Analysis

What Halozyme Therapeutics Does

Biotechnology Health Care

Halozyme Therapeutics makes drug-delivery technology that helps injectable medicines move from an IV infusion to a shot under the skin. Its core product is a recombinant enzyme used with partner drugs so patients can receive certain therapies faster and more conveniently in outpatient settings. The company also develops and sells this enzyme in forms used by its pharmaceutical partners and in hospital care.

Headquarters
United States of America US
Employees
423
IPO date
Jan 30, 2003
Read the full company overview
View Company Overview

Halozyme Therapeutics has a wide economic moat

No Moat Narrow Wide

Patent protection keeps rivals from freely copying Halozyme’s injection technology, while its inclusion in approved medicines makes replacement costly and time-consuming. Together, these barriers help Halozyme retain drug-company partners and collect payments tied to their medicine sales.

Read the full moat analysis
Financials
Efficiency

Earnings Waterfall
Halozyme Therapeutics Inc

Wall St Price Targets

Capital Returns

Buyback Yield
LOCKED
Debt Paydown Yield
LOCKED

Competitive Landscape

Ownership

HALO Insider Trading
Buy and sell transactions by insiders

Continue HALO Research

Summary
HALO intrinsic value, competitors valuation, and company profile.
DCF Valuation
HALO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HALO stock valuation using valuation multiples.
Wall St Estimates
HALO price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financial Statements
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HALO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financial Statements
Discount Rate
Other Halozyme Therapeutics Inc listings:
F • EUR
RV7
 SWB • EUR
RV7
 LSE • USD
0J2O
Discover More
What is the Intrinsic Value of one HALO stock?

The intrinsic value for Halozyme Therapeutics Inc (HALO) under the Base Case is hidden USD.

Is HALO stock undervalued or overvalued?

Compared with the current market price of 130.915 USD, the stock appears hidden.

Back to Top
ALPHA SPREAD
Follow us
Join 362,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.